P-02.04 Developing T cell bispecific antibodies with reduced-affinity anti-CD3 binders for a potent, efficacious, and low-cytokine response
Omar Abdelmotaleb(Roche (Switzerland)), Anina Schneider(University of Lausanne), Miro J. Eigenmann(Roche (Switzerland)), Sara Colombetti(Roche (Switzerland)), Alex Odermatt(University of Basel), Anne Freimoser–Grundschober(Roche (Switzerland)), Martin Lechmann(Roche (Switzerland)), Ali Bransi(Roche (Switzerland)), Peter Brünker(Roche (Switzerland)), C Klein(Roche (Switzerland)), Johannes Sam(Roche (Switzerland)), Inja Waldhauer(Roche (Switzerland)), Thomas Höfer(Heidelberg University)
Cited by 0
Related Papers
Charting biologically relevant chemical space: A structural classification of natural products (SCONP)
|Proceedings of the National Academy of Sciences|2005|552
Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation
|The Journal of Cell Biology|2004|468
MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis
|Nature Cancer|2022|224
Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection
|Proceedings of the National Academy of Sciences|2003|170